Tumor Registry of Lymphatic Neoplasia (TLN-Registry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00889798|
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : May 18, 2020
|Condition or disease|
|Non-Hodgkin's Lymphoma (NHL) Chronic Lymphocytic Leukemia (CLL) Multiple Myeloma (MM)|
The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||3795 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.|
|Study Start Date :||April 2009|
|Actual Primary Completion Date :||August 31, 2019|
|Actual Study Completion Date :||August 31, 2019|
- Course of treatment (treatment reality) [ Time Frame: 5 years per patient ]Documentation of anamnestic data and therapy sequences
- Effectiveness of treatment [ Time Frame: 5 years per patient ]Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889798
|Study Chair:||Wolfgang Knauf, MD||Center for Haematology, Frankfurt, Germany|
|Study Chair:||Wolfang Abenhardt, MD||MVZ Onkologie im Elisenhof, München, Germany|